Autoantibodies against Cardiac Troponins

Abstract

Cardiac troponins are preferred markers of tissue injury in acute coronary syndromes. Their specificity and the fact that only very minute amounts or none are normally found in the circulation provide high clinical sensitivity and specificity even when cardiac lesions are small. The importance of cardiac troponins in identifying high-risk patients to receive active intervention is widely recognized.¹